# Modulation of the Gut Microbiome With Pembrolizumab Following Chemotherapy in Resectable Pancreatic Cancer

> **NCT05462496** · PHASE2 · RECRUITING · sponsor: **Icahn School of Medicine at Mount Sinai** · enrollment: 25 (estimated)

## Conditions studied

- Pancreatic Cancer

## Interventions

- **PROCEDURE:** Biopsy
- **DRUG:** FOLFIRINOX
- **DRUG:** Ciprofloxacin
- **DRUG:** Metronidazole
- **DRUG:** Pembrolizumab
- **PROCEDURE:** Surgical Resection

## Key facts

- **NCT ID:** NCT05462496
- **Lead sponsor:** Icahn School of Medicine at Mount Sinai
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-03-16
- **Primary completion:** 2027-08
- **Final completion:** 2028-04
- **Target enrollment:** 25 (ESTIMATED)
- **Last updated:** 2024-10-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05462496

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05462496, "Modulation of the Gut Microbiome With Pembrolizumab Following Chemotherapy in Resectable Pancreatic Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05462496. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*